Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma

Safety and Efficacy of Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Malignant Melanoma of the Uvea

The purpose of this study is to assess the safety and efficacy of hypofractionated stereotactic LINAC radiotherapy with 10 fractions at 6 Gy per fraction at the 80% isodose for the planning target volume (PTV) in patients with uveal melanoma. Patients will be followed-up for 10 years after radiotherapy regarding local tumor control, visual acuity, secondary complications and survival.

Inclusion Criteria:

• The initial height of the melanoma is 7 mm or higher.
• Juxtapapillary and/or juxtamacular melanomas with a height of 3 mm or higher and if the central tumor distance to the optic disc and/or the macula is 3 mm or less.
• If other forms of conservative treatment of the melanoma are not possible.

Exclusion Criteria:

• Prior/Concomitant Treatment.
• Extrascleral tumor extension is present.
• If the presence of neovascular glaucoma is detected before treatment.
• If metastasis is detected at baseline.
• Previous participation in any study of investigational drugs within 3 month preceding day 0.
• Pregnant women are not allowed to participate in the study.